# Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.

> **NCT03281291** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1500 (actual)

## Conditions studied

- Malaria

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03281291
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2022-04-22
- **Final completion:** 2023-10-23
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281291, "Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03281291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*